title: Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B.
abstract: OBJECTIVE
  To assess the association between gene polymorphisms (single nucleotide polymorphisms [SNPs]) of rs8099917 and rs12980602 in the IL-28 gene and the response to lamivudine treatment in naïve of Chinese rural patients.
  
  
  METHODS
  Three hundred and fifty-four naïve chronic hepatitis B (CHB) patients treated with lamivudine were enrolled in this study. Rs8099917 and rs12980602 SNPs were genotyped using matrix-assisted laser desorption/ionization time of flight mass spectrometry. Baseline characteristics and genotypes were compared between 181 patients with treatment response and 173 without response.
  
  
  RESULTS
  The IL-28 genotypes were independently associated with responses at 1 year post-treatment with lamivudine in CHB patients (OR for rs8099917 GT/GG vs. TT, 4.097 [95% CI, 1.342-12.512; p = 0.015]; OR for rs12980602CT/CC vs. TT, 2.27 [95% CI, 1.202-4.284; p =0.014]). When adjusting for age, gender, smoking, drinking, and levels of hepatitis B virus (HBV) DNA, alanine aminotransferase, and HBV genotype, the rs8099917 genotype GT (OR, 4.025 [95% CI, 1.316-12.354; p = 0.013] and fibrosis stage (OR, 0.716 [95% CI, 0.432-0.986; p = 0.036] appeared to be associated with a higher probability of response to lamivudine treatment.
  
  
  CONCLUSIONS
  The genotype G/T for rs8099917 of IL-28 gene and early fibrosis stage may be predictive of treatment success.
authors.affiliation: Division of gastroenterology, The Second Hospital of Hebei Medical University, The Hebei Key Laboratory of Gastroenterology, Shijiazhuang, China. fengxue2002yu202356@hotmail.com
authors.forename: Fengxue
authors.initials: F
authors.lastname: Yu
authors.forename: Yanping
authors.initials: Y
authors.lastname: Wang
authors.forename: Shang
authors.initials: S
authors.lastname: Yuan
authors.forename: Junji
authors.initials: J
authors.lastname: Ma
authors.forename: Ning
authors.initials: N
authors.lastname: Ma
authors.forename: Xiaolin
authors.initials: X
authors.lastname: Zhang
authors.forename: Xuehui
authors.initials: X
authors.lastname: Liu
authors.forename: Dianwu
authors.initials: D
authors.lastname: Liu
mesh_terms: D000328:Adult; D044466:Asian People / Q000235:genetics*; D002681:China; D004279:DNA, Viral / Q000097:blood; D005260:Female; D005355:Fibrosis / Q000473:pathology; D005838:Genotype; D006515:Hepatitis B virus; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D006801:Humans; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D012424:Rural Population; D016896:Treatment Outcome; D000095022:Interferon Lambda
chemical_list: D004279:DNA, Viral; D007372:Interferons; D007378:Interleukins; D019259:Lamivudine; D018894:Reverse Transcriptase Inhibitors; C000624353:interferon-lambda, human; D000095022:Interferon Lambda